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INTRODUCTION
A standardized extract of cultured Lentinula edodes mycelia (ECLM) is an extract from cultured Lentinula edodes that reportedly exerts immune-protective effects against many types of cancer, including liver, breast, colon, and prostate [1] [2] [3] [4] . In a recent study, ECLM was also reported to suppress breast cancer stem cell proliferation by regulating the expression of microRNAs (miRNAs) [5, 6] . These miRNAs are controlling genes involved in cellular processes such as inflammation, cell cycle regulation, stress response, differentiation, apoptosis, and migration [7] . Natural antisense RNAs (ASs), comprising a type of protein non-coding RNA, have been reported to regulate the expression of protein-coding genes by acting as a competing endogenous RNA (ceRNA) that adsorbs miRNAs resulting in the prevention of mRNA degradation; further, they can also form a transient RNA duplex [8] [9] [10] .
EphA2, a receptor tyrosine kinase, is typically expressed at low levels in normal epithelial cells, whereas its overexpression has been widely observed in numerous solid tumors and is associated with cell transformation, primary tumor initiation, and tumor progression [11] .
Therefore, we verified the possibility that ECLM regulated the expression of EphA2 mRNA by regulating EphA2 AS expression and suppresses breast cancer cell proliferation. We also verified the possibility that AS could function as a ceRNA for EphA2 as well.
MATERIALS AND METHODS

Cell culture
Human MDA-MB-231 cells (originating from mammary adenocarcinoma; ATCC HTB-26) were maintained in RPMI-1640 medium supplemented with 10% heat-inactivated fetal calf serum (FCS) (R10 medium). Human MCF7 cells (originating from mammary adenocarcinoma; ATCC HTB-22) were maintained in Dulbecco's Modified Eagle's Medium (D-MEM) containing 10% FCS, 0.1 mM non-essential amino acids, and 1 mM sodium pyruvate (D10 medium).
To examine the effect(s) of ECLM (Amino Up Chemical, Sapporo, Japan) on EphA2 AS and mRNA expression levels and the potential effects as a ceRNA, MDA-MB-231 cells were maintained in R10 medium supplemented with this compound at 1.25 mg/ml, 0.625 mg/ml and 0 mg/ml; cells were sub-cultured three times. MCF7 cells were maintained in D10 medium supplemented with this compound at 0.625 mg/ml and 0 mg/ml, and cells were also sub-cultured three times.
Measurement of lactate dehydrogenase (LDH) activity
As an indicator of cytotoxicity, LDH activity in the medium was measured in triplicate using LDH Cytotoxicity Detection Kits (Takara Bio, Otsu, Japan), according to the manufacturer's instructions.
Oligonucleotides
Unconjugated locked nucleic acid (LNA)-modified anti-miR-126, anti-miR-335, and anti-miR-4267 oligonucleotides were synthesized with a complete phosphorothioate backbone (Gene-Design, Osaka, Japan). The sequence of antimiR-126, anti-miR-335, and anti-miR-4267 were Page 194 of 205 complementary to the seed region of mature miR-126, miR-335, and miR-4267 (nucleotides 2-9), respectively. The LNA mismatch control was designed according to the miR-126 seed region sequence.
Strand-specific reverse-transcription quantitative polymerase chain reaction (RT-qPCR)
DNase I-treated total cellular RNA was annealed with strand-specific primers. cDNA was synthesized in both the presence and absence of 100 U ReverTra Ace (TOYOBO, Osaka, Japan) at 50 °C for 30 min. The cDNAs were then amplified by PCR using rTaq DNA Polymerase (TOYOBO) in a Thermal Cycler Dice Real Time System II (TaKaRa Bio, Shiga, Japan) using the following default thermocycler program: 1 min of pre-incubation at 95 °C followed by 22-38 cycles of 15 s at 95 °C, 1 min at 72 °C (reducing the annealing temperature 0.3 °C per cycle), and 30 s at 72 °C. The primers used for RT and PCR of AS, mRNA, and 18S rRNA are shown in Table 1 . 
RNA preparation and RNA-seq
Total cellular RNA was isolated from MDA-MB-231 and MCF7 cells using Sepasol®-RNA I Super G (Nacalai tesque, Kyoto, Japan). RNA samples were then treated with proteinase K (Wako, Osaka, Japan) and TURBO DNA-free DNase I kit (Applied Biosystems, Carlsbad, USA) to remove RNase and genomic DNA.
For RNA-seq, ribosomal RNA was removed using the Ribo-Zero rRNA Removal Kit (Illumina, San Diego, USA), according to the manufacturer's instructions.
Sequence libraries were generated using TruSeq Stranded Total RNA Sample Prep Kit (Illumina). The libraries were then sequenced on an Illumina Hiseq 2500 platform, and 100-bp pair-end reads were generated. Sequence reads were analyzed for expression levels using the CLC genomics workbench (QIAGEN, Hilden, Germany).
Plasmid construction
To construct the pEF-luc-EphA2 AS reporter plasmid, EphA2 AS was amplified by PCR using pCG-EphA2 AS (accompanying paper) as a template. EphA2 AS was digested with XbaI and ligated into the XbaI site of the pEF-luc-SVpA [12] reporter vector.
To construct the pEF-luc-EphA2 AS miR response element (MRE)-126 seed revertant (SR), MRE-335SR, and MRE-4267SR, PCR and the Gibson assembly system were employed using the Q5 High-Fidelity DNA Polymerase (New England Biolabs, Ipswich, USA) and Gibson Assembly Master Mix (New England Biolabs, Ipswich, USA), according to the manufacturer's instructions.
Primers for construction of the above vectors are shown in Table 2 . These MRE revertants were changed MRE sequences to these complementary sequences. 
Luciferase reporter assays
To analyze the effect of miRNA and ECLM on EphA2 AS and mRNA expression, we performed luciferase reporter assays. For reporter gene assays, 6.2 × 10 5 MDA-MB-231 cells/well were transfected with a luciferase reporter plasmid (0.3 μg/well) using Lipofectamine 3000 (Invitrogen, Carlsbad, USA). Cells were co-transfected with the pRL-RSV plasmid encoding Renilla luciferase (0.8 μg/well), to control for differences in transfection efficiency.
Firefly and Renilla luciferase activities were measured using the Dual-Luciferase Reporter Assay System (Promega), according to the manufacturer's instruction. Protein concentrations were measured using the Protein Assay BCA Kit (Wako, Osaka, Japan). Firefly luciferase activity was normalized to Renilla luciferase activity and the amount of total protein.
Statistical analysis and informatics
Differences presented in the figures were analyzed by performing a Student's t test.
RESULTS
ECLM suppresses the proliferation of human breast cancer cells
We first investigated whether ECLM inhibits proliferation in breast cancer cells by cell counting.
ECLM significantly suppressed proliferation at concentrations of 0.625 mg/ml for MCF7 cells (48 hr) and 1.25 mg/ml for MDA-MB-231 cells (48-72 hr). These results indicated that ECLM functions during periods of the low confluence with poor cell adhesion. In addition, ECLM at a concentration of 1.25 mg / ml completely inhibited the growth of MCF7 cells (data not shown).
The cytotoxicity of ECLM toward MDA-MB-231 cells was observed 24 h after sub-culture, but not after 48 h of sub-culture, at which time cell proliferation was suppressed ( Fig.1 ).
Identification of a naturally occurring antisense transcript overlapping human EPHA2
To determine whether EphA2 AS is expressed in MDA-MB-231 cells we employed RNA-seq.
This revealed the presence of reads corresponding to the opposite strand of EPHA2, which were widely distributed in the region overlapping mRNA exon 1-17, and included the overlapping EphA2 mRNA3′UTR. (Table 3 ).
Effect of ECLM on EphA2 antisense and mRNA levels
We next examined the effect of ECLM on the expression levels of EphA2 AS and mRNA in MDA-MB-231 and MCF7 cells. Levels of EphA2 AS and mRNA were concordantly suppressed by ECLM in MDA-MB-231 (accompanying paper) and MCF7 cells (Fig. 2) .
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EphA2 antisense regulates the miRNA-independent expression of EphA2 mRNA A recent study showed that AS sequences sharing miRNA response elements (MREs) with coding transcripts can be similarly targeted, resulting in the sequestering of miRNAs to prevent them from acting on mRNAs. Bioinformatics analysis (RegRNA [13] , RNAhybrid [14] , miRDB [15] , and PITA [16] ) was performed to predict the MREs that are shared by EphA2 AS and EphA2 mRNA 3′UTR, and these were predicted to share several MREs (MRE-126, MRE-335, and MRE-4267; Fig.3) . 
Validation of miR-126, miR-335, and miR-4267 MREs in EphA2 AS and mRNA
To validate the presence of miR-126, miR-335, and miR-4267 MREs in EphA2 AS and mRNA, we assessed the effect of endogenous miR-126, miR-335, and miR-4267 expression on EphA2 AS and mRNA levels by employing an anti-miR approach to inhibit endogenous miR expression [17] .
For this knockdown strategy, we designed 8-mer anti-miR-126, miR-335, and miR-4267 sequences, using a fully LNA-modified phosphorothioate oligonucleotide complementary to the seed region of these miRNAs. We then tested their effects on EphA2 AS and mRNA expression in non-ECLM treated MDA-MB-231 cells. Silencing endogenous miR-335 increased EphA2 AS and mRNA levels by 36-and 28-fold, respectively, compared to expression with an LNA mismatch control ( Fig. 4) . To verify specific MRE-miRNA interactions, we used MRE-inverted luciferase reporters.
Inverse MRE-126, MRE-335, and MRE-4267 sequences in EphA2 AS were inserted downstream of the luciferase reporter gene and their effects were tested on luciferase reporter activity using pLKO-miR-126, pLKO-miR-335, and pLKO-miR-4267 virus-transduced cells (Fig. 6 ). These transduced cells were overexpressed these miRs (data not shown). MiR-126, -335, and -4267 MRE-inverted luciferase reporters in the corresponding miRNA transduced cell, there are no increase in luciferase activity was observed, indicating that these miRNAs did not affect EphA2
AS expression. In addition, similar results was obtained for miR-126, -335, and -4267 MRE triple-inverted luciferase reporter in the parental cell. 
DISCUSSION
ECLM was previously reported to have various anti-cancer effects via an immune-protective effect and through the regulation of miRNA expression [1] [2] [3] [4] [5] . ECLM is also known to reduce the risk of adverse neutrophil events in breast cancer patients who received adjuvant chemotherapy at 3 g/day oral administration [2] . These reports suggested that ECLM is useful for both the treatment of breast cancer and the prevention of chemotherapy side effects. luciferase reporter assays were also performed for EphA2 AS (C) and EphA2 mRNA (D) activity.
EphA2, which is highly expressed in triple-negative breast cancer, forms a heterodimer with EGFR and is involved in cell proliferation [18] . Accordingly, the delivery of EphrinA1 to tumor tissues, which is involved in the suppression of EphA2, as well as methods using siRNA against EphA2 and antibodies have been examined [19] [20] [21] . Compared to these methods, the suppression of breast cancer cell proliferation by inhibiting of EphA2 AS and mRNA expression via ECLM administration is advantageous in that the oral administration of this compound is and safe.
The possibility that EphA2 AS functions as a ceRNA to protect mRNA could be confirmed by miR-335 neutralization experiments; however, the negative results obtained herein did not support this effect. Therefore, it is thought that there is a regulating mechanism by non-ceRNA effect including mRNA stabilization through sense-antisense duplex formation reported [8] .. 
CONCLUSION
ECLM suppresses the proliferation of breast carcinoma cells in a specific dose-dependent manner and inhibits both EphA2 AS and mRNA expression. However, this regulatory event did not appear to occur through a ceRNA effect. These results thus suggest that ECLM could regulate EphA2 AS and mRNA expression by not ceRNA effect, thereby stabilizing EphA2 mRNA. Therefore, it is necessary to further examine this regulation mechanism.
